Optimization of time to initial vancomycin target trough improves clinical outcomes
Open Access
- 19 July 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in SpringerPlus
- Vol. 4 (1), 1-14
- https://doi.org/10.1186/s40064-015-1146-9
Abstract
Outcomes data for the efficacy of interventions designed to decrease the time to initial target vancomycin troughs are sparse. A vancomycin therapeutic drug monitoring (TDM) program was initiated to reduce the time to initial target troughs and to examine the impact on clinical outcomes. Single-center, pre- and post-intervention observational study in a 250 bed teaching facility. Adult inpatients treated with physician-guided, vancomycin therapy (historical control, CTRL) were compared to high trough, pharmacist-guided vancomycin therapy (TDM). Nephrotoxicity analyses were conducted to the ensure safety of the TDM. Clinical outcome analysis was limited to patients with normal renal function and culture-confirmed gram positive infections and a pre-defined MRSA subset. 340 patients met initial inclusion criteria for the nephrotoxicity analysis (TDM, n = 173; CTRL, n = 167). Acute kidney injury occurrence was similar between the CTRL (n = 20) and TDM (n = 23) groups (p = 0.7). Further exclusions yielded 145 patients with gram positive infections for clinical outcomes evaluation (TDM, n = 66; CTRL, n = 75). The time to initial target trough was shorter in the TDM group (3 vs. 5 days, p < 0.001). Patients in the TDM group discharged from the hospital more rapidly, 7 vs. 14 days (Hazards Ratio (HR), 1.41; 95% Confidence Interval [CI] 1.08–1.83; p = 0.01), reached clinical stability faster, 4 vs. 8 days (HR, 1.51; 95% CI 1.08–2.11; p = 0.02), and had shorter courses of vancomycin, 4 vs. 7 days (HR, 1.5; 95% CI 1.15–1.95; p = 0.003). In the MRSA infection subset (TDM, n = 36; CTRL, n = 35), patients in the TDM group discharged from the hospital more rapidly, 7 vs. 16 days (HR, 1.89; 95% CI 1.08–3.3; p = 0.03), reached clinical stability faster, 4 vs. 6 days (HR, 2.69; 95% CI 1.27–5.7; p = 0.01), and had shorter courses of vancomycin, 5 vs. 8 days (HR, 2.52; 95% CI 1.38–4.6; p = 0.003). Attaining initial target troughs in <5 days versus ≥5 days was associated with improved clinical outcomes. All cause in-hospital mortality, and vancomycin treatment failure occurred at comparable rates between groups. Interventions designed to decrease the time to reach initial target vancomycin troughs can improve clinical outcomes in gram positive infections, and in particular MRSA infections.Keywords
This publication has 54 references indexed in Scilit:
- Evaluation of Vancomycin Susceptibility Testing for Methicillin-Resistant Staphylococcus aureus: Comparison of Etest and Three Automated Testing MethodsJournal of Clinical Microbiology, 2013
- High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysisInternational Journal of Infectious Diseases, 2013
- Evaluation of a vancomycin dosing nomogram in achieving high target trough concentrations in Taiwanese patientsInternational Journal of Infectious Diseases, 2012
- Effects of Targeting Higher Vancomycin Trough Levels on Clinical Outcomes and Costs in a Matched Patient CohortPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012
- Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled StudyClinical Infectious Diseases, 2012
- Implementation and evaluation of vancomycin nomogram guidelines in a computerized prescriber-order-entry systemAmerican Journal of Health-System Pharmacy, 2010
- Vancomycin Dosing for Pneumonia in Critically Ill Trauma PatientsThe Journal of Trauma and Acute Care Surgery, 2009
- Early antibiotic treatment failureInternational Journal of Antimicrobial Agents, 2009
- Vancomycin administration: the impact of multidisciplinary interventionsJournal of Clinical Pathology, 2007
- Impact of Vancomycin Therapeutic Drug Monitoring on Patient CareAnnals of Pharmacotherapy, 1994